Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239900 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 143
- Enrollment target
NCT02239900: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02239900 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 143 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02239900, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 143 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of ipilimumab and stereotactic body radiation therapy (SBRT). The safety and effectiveness of these treatments given consecutively will also be studied. This is an investigational study. SBRT is FDA approved for the control of metastatic and primary tumors. Ipilimumab is FDA approved and commercially available for the treatment of metastatic melanoma that cannot be removed with surgery. The use of SBRT with ipilimumab is investigational. The study doctor can explain how the study drug is designed to work. Up to 120 participants will be enrolled in this study. All will take part at MD Anderson.
Interventions
- DRUG Ipilimumab
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2014-08-26 |
| Est. Completion | 2019-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02239900
The ClinicalTrials.gov registry entry for NCT02239900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT02239900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02239900 about?
NCT02239900 is a clinical study titled "Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors". The goal of this clinical research study is to find the highest tolerable dose of ipilimumab and stereotactic body radiation therapy (SBRT). The safety and effectiveness of these treatments given consecutively will also be studied. This is an investigational study. SBRT is FDA approved for the cont...
What is the current status of trial NCT02239900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 143 participants. The study started on 2014-08-26. Estimated completion is 2019-10-25.
What interventions are being tested in trial NCT02239900?
The interventions under investigation include: Ipilimumab (DRUG), Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT02239900?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.